Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

RVL Pharmaceuticals plc (RVLP)

1.47   0.01 (0.68%) 11-25 13:00
Open: 1.43 Pre. Close: 1.46
High: 1.47 Low: 1.39
Volume: 23,420 Market Cap: 146(M)

Technical analysis

as of: 2022-11-25 2:00:07 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.95     One year: 2.23
Support: Support1: 1.28    Support2: 1.07
Resistance: Resistance1: 1.67    Resistance2: 1.9
Pivot: 1.5
Moving Average: MA(5): 1.48     MA(20): 1.57
MA(100): 1.89     MA(250): 1.59
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 42.5     %D(3): 38.8
RSI: RSI(14): 39.7
52-week: High: 2.99  Low: 0.98
Average Vol(K): 3-Month: 161 (K)  10-Days: 63 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RVLP ] has closed above bottom band by 38.6%. Bollinger Bands are 53.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.56 - 1.57 1.57 - 1.58
Low: 1.39 - 1.4 1.4 - 1.41
Close: 1.45 - 1.46 1.46 - 1.47

Company Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Headline News

Mon, 14 Nov 2022
RVLP: Can’t Take My Eyes Off You - Yahoo Finance

Thu, 10 Nov 2022
RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript - Seeking Alpha

Mon, 07 Nov 2022
New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing -

Fri, 04 Nov 2022
RVL Pharmaceuticals (RVLP) to Release Earnings on Thursday - MarketBeat

Sat, 08 Oct 2022
RVL Pharmaceuticals plc's (NASDAQ:RVLP) largest shareholders are private equity firms who were rewarded as market cap surged US$25m last week - Simply Wall St

Thu, 22 Sep 2022
RVL Pharmaceuticals Stock: A Developing Quandary (RVLP) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 99 (M)
Shares Float 33 (M)
% Held by Insiders 26.1 (%)
% Held by Institutions 49.8 (%)
Shares Short 345 (K)
Shares Short P.Month 401 (K)

Stock Financials

EPS -0.86
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.68
Profit Margin (%) -124.2
Operating Margin (%) -127.7
Return on Assets (ttm) -25.8
Return on Equity (ttm) -86.1
Qtrly Rev. Growth 356.3
Gross Profit (p.s.) 0.13
Sales Per Share 0.43
EBITDA (p.s.) -0.55
Qtrly Earnings Growth 0
Operating Cash Flow -46 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -1.72
PEG Ratio 0
Price to Book value 2.13
Price to Sales 3.4
Price to Cash Flow -3.19

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.